Wall Street analysts expect that Flexion Therapeutics Inc (NASDAQ:FLXN) will announce $18.85 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Flexion Therapeutics’ earnings, with the lowest sales estimate coming in at $18.70 million and the highest estimate coming in at $19.00 million. Flexion Therapeutics posted sales of $6.99 million during the same quarter last year, which suggests a positive year-over-year growth rate of 169.7%. The firm is expected to report its next quarterly earnings results on Wednesday, November 6th.

On average, analysts expect that Flexion Therapeutics will report full year sales of $67.45 million for the current fiscal year, with estimates ranging from $61.50 million to $70.80 million. For the next fiscal year, analysts expect that the company will post sales of $142.30 million, with estimates ranging from $127.60 million to $169.30 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Flexion Therapeutics.

Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.96) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.06) by $0.10. Flexion Therapeutics had a negative return on equity of 175.29% and a negative net margin of 368.31%. The company had revenue of $16.95 million during the quarter, compared to the consensus estimate of $14.03 million.

A number of equities research analysts have recently weighed in on the company. Northland Securities set a $20.00 target price on Flexion Therapeutics and gave the stock a “buy” rating in a report on Tuesday, September 10th. Zacks Investment Research raised Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Saturday, August 10th. BidaskClub raised Flexion Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, September 4th. Finally, ValuEngine raised Flexion Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Ten equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $23.57.

Shares of FLXN traded up $0.18 during midday trading on Thursday, reaching $14.72. 406,107 shares of the stock were exchanged, compared to its average volume of 620,843. Flexion Therapeutics has a twelve month low of $8.76 and a twelve month high of $19.82. The company has a quick ratio of 7.33, a current ratio of 7.80 and a debt-to-equity ratio of 3.95. The company has a market cap of $554.83 million, a P/E ratio of -3.28 and a beta of 1.23. The stock’s 50 day simple moving average is $11.92 and its 200 day simple moving average is $11.69.

In related news, insider Michael D. Clayman purchased 2,317 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was acquired at an average price of $10.85 per share, with a total value of $25,139.45. Following the completion of the purchase, the insider now directly owns 72,249 shares in the company, valued at $783,901.65. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 16.01% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Quantamental Technologies LLC raised its stake in Flexion Therapeutics by 310.1% in the second quarter. Quantamental Technologies LLC now owns 3,449 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 2,608 shares in the last quarter. Aperio Group LLC acquired a new position in Flexion Therapeutics in the second quarter valued at about $46,000. Cutler Group LP raised its stake in Flexion Therapeutics by 2,650.0% in the second quarter. Cutler Group LP now owns 5,500 shares of the specialty pharmaceutical company’s stock valued at $67,000 after purchasing an additional 5,300 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in Flexion Therapeutics by 53,692.3% in the first quarter. BNP Paribas Arbitrage SA now owns 6,993 shares of the specialty pharmaceutical company’s stock valued at $87,000 after purchasing an additional 6,980 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY acquired a new position in Flexion Therapeutics in the second quarter valued at about $123,000. 84.84% of the stock is owned by institutional investors and hedge funds.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

See Also: Convertible Shares

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.